HLB Starts Rivoceranib Site Planning to Diversify Supply Chain

[Kim Jinsoo, Edaily Reporter] HLB Pharma, an affiliate of HLB Group, announced today that it has begun conceptual design work to produce its targeted anti-cancer drug, rivoceranib, at its Hyangnam facility in South Korea.

The move marks a strategic shift toward in-house manufacturing and aims to reduce potential supply chain risks stemming from U.S.-China geopolitical tensions.

HLB Pharma Hyangnam site.